Skip to main content
Novartis AG logo

Novartis AG — Investor Relations & Filings

Ticker · NOVN ISIN · CH0038459415 LEI · 5493007HIVTX6SY6XD66 SW Manufacturing
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2018-02-15 Director's Dealing
Country CH Switzerland
Listing SW NOVN

About Novartis AG

https://www.novartis.com/

Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2018-02-15 English
SC 13G
Major Shareholding Notification
2018-02-14 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to SEC rules. It contains a media release announcing clinical trial results for a drug (brolucizumab) in Phase III studies, including detailed efficacy and safety data. The document is not an annual or quarterly report, nor is it an earnings release or management discussion. It is a regulatory filing used by foreign companies to report material information to the SEC between annual reports. The content is primarily a press release with clinical trial data and forward-looking statements, typical of a Form 6-K filing. Therefore, the document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2018-02-09 English
FORM 6-K
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to SEC rules. It announces the completion of a tender offer for Advanced Accelerator Applications S.A., including details about the offer period, shares tendered, and payment. The document includes disclaimers, contact information, and signatures but does not contain detailed financial statements or comprehensive financial analysis. It is primarily an announcement of a corporate action related to a tender offer, which is a financing/capital structure event. The document is not an annual or interim report, audit report, earnings release, or other financial report type. It fits best under Capital/Financing Update (CAP) as it provides an update on a financing activity (tender offer completion). The document length (8579 characters) and content confirm it is a substantive announcement, not just a brief notice or certification, supporting a confident classification as CAP.
2018-02-01 English
SC 13D
Major Shareholding Notification
2018-02-01 English
Novartis completes subsequent offering period of the tender offer for Advanced Accelerator Applications S.A.
AGM Information Classification · 99% confidence The document is a press release dated February 1, 2018, announcing the completion of a subsequent offering period for a tender offer by a Novartis subsidiary to acquire shares of Advanced Accelerator Applications S.A. (AAA). The text explicitly mentions filing a 'Tender Offer Statement on Schedule TO' and AAA filing a 'Solicitation/Recommendation Statement on Schedule 14D-9' with the SEC. A tender offer and related solicitation/recommendation statements are core components of a takeover or merger activity. Therefore, the most appropriate classification is M&A Activity (TAR). It is not a general earnings release (ER), an annual report (10-K), or a proxy statement (PSI).
2018-02-01 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.